DOCSLIB.ORG

Elizabeth M. Andal V. Celera Corporation, Et Al. 11-CV-01769

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Elizabeth M. Andal V. Celera Corporation, Et Al. 11-CV-01769 Case3:11-cv-01769-SC Document1 Filed04/11/11 Page1 p1 I Jennie Lee Anderson (SBN 203586) ANDRUS ANDERSON LLP " 2 155 Montgomery Street, Suite 900 A San Francisco, California 94104 3 Telephone: (415) 986-1400 Facsimile: (415) 986-1474 4 [email protected] 5 DAVID A. P. BROWER (pro hac vice pending) BRIAN C. KERR (pro hac vice pending) 6 BROWER PP/EN A PROFESSIONAL CORPORATION 7 488 Madison Avenue, Eighth Floor New York, NY 10022 8 Telephone: (212) 501-9000 Facsimile: (212) 501-0300 9 Attorneys for Plaintiff 10 E1nQ 11 UNITED STATES DISTRICT COURT 12 NORTHERN DISTRICT OF CALIFORNIA 13 ELIZABETH M. ANDAL, Individually and behalf of all others similarly situated, V° iLi 1769 Plaintiff, CLASS ACTION V. COMPLAINT FOR BREACH OF FIDUCIARY DUTIES AND CELERA CORPORATION, QUEST VIOLATIONS OF SECTIONS DIAGNOSTICS INCORPORATED, SPARK 14(e) AND 20(a). OF THE ACQUISITION CORPORATION, RICHARD SECURITIES EXCHANGE ACT H. AYERS, JEAN-LUC BEL1NGARD, OF 1934 WILLIAM G. GREEN, PETER BARTON 19 HUTT, GAIL K. NAUGHTON, KATHY ORDONEZ, WAYNE I. ROE, AND JURY TRIAL DEMANDED 20 BENNETT M. SHAPiRO, 21 22 Plaintiff, individually and on behalf of all others similarly situated, respectfully brings this 23 shareholder class action for breach of fiduciary duty and violations of Sections 14(e) and 20(a) of 24 the Securities Exchange Act of 1934 ("1934 Act"), and US Securities and Exchange Commission 25 ("SEC") Rule 14a-9 promulgated thereunder against the herein named defendants and alleges the 26 following upon information and belief, except as to those allegations specifically pertaining to 27 plaintiff, which are predicated upon the investigation undertaken by Plaintiff's counsel: 28 COMPLAINT FOR BREACH OF FIDUCIARY DUTY Case3:11-cv-01769-SC Document1 Filed04/11/11 Page2 of 30 1 NATURE OF THE ACTION 2 1. This is a shareholder class action brought by plaintiff on behalf of all similarly 3 situated public shareholders of Celera Corporation ("Celera" or the "Company") against the 4 company and its Board of Directors ("Individual Defendants" or the "Board"), among others, in 5 connection with the proposed buyout of Celera by Quest Diagnostics Incorporated ("Quest"), 6 through its subsidiary Spark Acquisition Corporation ("Merger Sub"), which was formed solely to 7 facilitate the transaction ("Proposed Transaction"). This matter arises out of defendants' 8 dissemination of a false and misleading Solicitation/Recommendation Statement in violation of 9 Sections 14(e) and 20(a) of the 1934 Act and SEC Rule 14a-9 promulgated thereunder, and the 10 Board's breaches of their fiduciary duties owed to Celera's stockholders under state law. 11 2. On March 17, 2011, Celera entered into an Agreement and Plan of Merger 12 ("Merger Agreement") with Quest, whereby Quest would, within a week of the deal's :13 announcement, commence a tender offer ("Tender Offer") to acquire all of the issued and 14 outstanding shares of Celera common stock for $8.00 per share in cash ("Proposed Transaction"). 15 3. At the same time, the Company shocked the market by filing a host of restatements 16 to its prior Securities and Exchange Commission ("SEC"). financial filings ("Restatements"). 17 These Restatements expose the fact that Celera's management has engaged in a wide-ranging 18 accounting fraud over the past several years, which included improperly classifying and reporting 19 bad debt expenses and unreimbursed and uncollectible charges. These fraudulent accounting 20 practices materially affected Celera's financial statements. The Restatements are so expansive and 21, damning that had they been disclosed independent of a merger announcement that propped up the 22 stock price, they would have exposed the Company's senior management, as well as the entire 23 Board, to possible liability for violating the federal securities laws. 24 4. As the need for the Restatements became apparent, Kathy Ordonez, Celera's Chief 25 Executive Officer, with the assistance of the rest of the Board, moved quickly to sell the Company 26 at any price in exchange for broad indemnity and continuing employment for Celera's senior 27 management team. 28 5. To effectuate a sale in advance of the Restatements, Ordonez and the Board were 1 COMPLAINT FOR BREACH OF FIDUCIARY DUTY Case3:11-cv-01769-SC Document1 Filed04/11/11 Page3 of 30 I forced to accept an offer from the Company's long-time strategic partner, Quest that was well 2 below what Quest had previously indicated it was prepared to pay for Celera. Quest had 3 previously offered over $10 a share for Celera, but revised its offer significantly downward in light 4 of defendants' demand for broad indemnification and senior management's request for continued 5 employment post-closing. This self-interested negotiating cost Celera shareholders maximum 6 value for their shares, as the Celera Board was eventually forced to accept the $8.00 price if they 7 were to (a) strike a deal in advance of the Restatements; and (b) secure the indemnification and 8 future employment for senior management that they sought, 9 6. Pursuant to the Merger Agreement, Quest will indemnify and hold harmless, to the 10 fullest extent permitted under applicable law, each present and former director, officer, employee 11 and agent of the Company and each Company subsidiary, for the unusually long period of six 12 years from the date of closing. 13 7. Moreover, the Proposed Transaction will help ensure that Celera's senior officers 14 and board members will receive a windfall by either receiving lucrative positions with Quest or 15 substantial severance benefits. Indeed, without the Proposed Transaction, these officers and 16 directors would be forced to deal with the pending securities litigation and the Restatements' 17 negative repercussions, including possible termination, additional lawsuits, and SEC-permitted 18 claw-backs. 19 8. To ensure consummation of this liability-absolving transaction, the Board also gave 20 Quest a panoply of deal protections, including a no-shop provision ("No-Shop"), unlimited 21 matching rights ("Matching Rights"), and a $23.45 million termination fee ("Termination Fee"), 22 which represents over 10% of the total value Quest is paying to acquire Celera's operations (i.e., 23 net of cash and tax assets, both of which have a fixed and objective value and therefore should not 24 be considered in assessing the reasonableness of the termination fee). 25 9. Celera and Quest structured the Proposed Transaction as a Tender Offer so that it 26 can close within a month of the deal's announcement. This effectively eliminates the prospect of a 27 competing bid because no interested suitor could arrange financing, present a "Superior Proposal" 28 (as defined in the Merger Agreement) sufficient to allow the Board to provide it with due 2 COMPLAINT FOR BREACH OF FIDUCIARY DUTY Case3:11-cv-01769-SC Document1 Filed04/11/11 Page4 of 30 1 1 diligence, wait through the three business day delay required by the Matching Rights, complete 2 due diligence, fully digest the Company's accounting problems and the Restatements, and finalize 3 the terms of an alternative takeover transaction within this compressed time period. To be sure the 4 Proposed Transaction can be consummated by short-form merger on an expedited basis, the Board 5 granted Quest a "Top-Up Option" that helps Defendants avoid the protracted process of a 6 shareholder vote. Not only would the extended timeframe of a long-form merger increase third 7 parties' ability to assemble and present a "Superior Proposal," it would also allow for shareholders 8 to fully digest the windfall of information recently disclosed and possibly vote down the Proposed 9 Transaction. 10 10. In an attempt to secure shareholder approval of this unfair deal, on March 28, 2011, 11 defendants filed a materially misleading Solicitation/Recommendation Statement ("Proxy"). The 12 Proxy recommends that Celera's shareholders accept the offer, tender their shares, and adopt the 13 Merger Agreement. However, the Proxy is misleading because among other things, it almost 14 wholly ignores material issues relating to the motivation for, and negotiation of, the Proposed 15 Transaction, including the Restatements; the ongoing Celera securities class action and 16 shareholder derivative lawsuit; and possible civil liability looming over the Celera Board and 17 senior management. Specifically, the Proxy omits and/or misrepresents the material information 18 set forth below in contravention of Sections 14(e) and 20(a) of the 1934 Act and/or defendants' 19 fiduciary duty of disclosure under state law. 20 11. As explained herein, this information is material to the impending decision of 21 Celera' s shareholders whether to tender their shares and vote in favor of the Proposed Transaction. 22 As such, defendants' violations of Sections 14(e) and 20(a) of the 1934 Act and their breaches of 23 fiduciary duty under state law to maximize shareholder value and disclose all material information 24 in connection with a merger transaction threaten shareholders with irreparable harm for which 25 money damages are not an adequate alternate remedy. Thus, plaintiff seeks injunctive relief to 26 ensure that defendants cure their breaches of fiduciary duty and violations of Sections 14(e) and 27 20(a) before Celera shareholders are asked to tender their shares and vote on the Proposed 281 Transaction, and that defendants are not permitted to seek shareholder support of the Proposed 3 COMPLAINT FOR BREACH OF FIDUCIARY DUTY Case3:11-cv-01769-SC Document1 Filed04/11/11 Page5 of 30 1 Transaction without complying with their duty under state law to maximize shareholder value and 2 the federal securities laws and state law to provide shareholders with all material information 3 about the sales process, the merger consideration, and the company's intrinsic value.
Load more

Recommended publications
  • In the Court of Chancery of the State of Delaware
    IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE NEW ORLEANS EMPLOYEES’ RETIREMENT SYSTEM, on behalf of itself and all other similarly situated shareholders of Celera Corporation, Plaintiff, v. C.A. No. _________ RICHARD H. AYERS, JEAN-LUC BELINGARD, WILLIAM G. GREEN, PETER BARTON HUTT, GAIL K. NAUGHTON, KATHY ORDONEZ, WAYNE I. ROE, BENNETT M. SHAPIRO, CELERA CORPORATION, QUEST DIAGNOSTICS INCORPORATED, AND SPARK ACQUISITION CORPORATION, Defendants. VERIFIED CLASS ACTION COMPLAINT Plaintiff, New Orleans Employees’ Retirement System (“NOERS” or “Plaintiff”), on behalf of itself and all other similarly situated public shareholders of Celera Corporation (hereafter, “Celera” or the “Company”), brings the following Verified Class Action Complaint (the “Complaint”) against the members of the board of directors of Celera (the “Celera Board” or “Board”) for breaching their fiduciary duties, and against Quest Diagnostics Incorporated (“Quest”) and Spark Acquisition Corporation (“Spark”) for aiding and abetting the same. The allegations of the Complaint are based on the knowledge of Plaintiff as to itself, and on information and belief, including the investigation of counsel and review of publicly available information as to all other matters. INTRODUCTION 1. This is a case about a corporate board that chose to negotiate an all-cash sale of the company while operating under the same material conflict of interest that lay at the heart of the Delaware Supreme Court’s ruling in Revlon, Inc. v. MacAndrews & Forbes, Inc., 506 A.2d 173 (Del. 1986). Over the weeks leading to this action, the Celera Board faced a clear choice: disclose a material accounting fraud and risk liability that would flow from that disclosure, or negotiate a desperate and rushed sale of the company at whatever price a potential bidder would offer in order to insulate themselves from liability and secure their own financial well-being.
    [Show full text]
  • Preliminary Healthcare Agenda 01.03X
    29th Annual J.P. Morgan Healthcare Conference January 10 - 13, 2011 Westin St. Francis Hotel, San Francisco, CA Preliminary Conference Agenda SUNDAY, JANUARY 9 - Registration in Tower Salon A - 3 to 9 PM MONDAY, JANUARY 10 - Registration in Tower Salon A - 6:45 AM, Breakfast in Italian Foyer Grand Ballroom Colonial Room California West California East Elizabethan A/B Elizabethan C/D Alexandra's Breakout: Borgia Room Breakout: Georgian Room Breakout: Olympic Room Breakout: Yorkshire Room Breakout: Sussex Room Private Company Track Not-for-Profit Track 7:30 AM Opening Remarks: Doug Braunstein - Chief Financial Officer, JPMorgan Chase & Co., Grand Ballroom Astra Tech 8:00 AM Celgene Corporation Kinetic Concepts, Inc Alkermes, Inc. Biocon Limited Catalent (private company) 8:30 AM Express Scripts Inc. Agilent Technologies Inc. Beckman Coulter Inc. Bio-Rad Laboratories, Inc. Quality Systems Axcan Intermediate Holdings 9:00 AM Roche Holding AG Zimmer Holdings, Inc. Genoptix, Inc. ImmunoGen, Inc Health Net Inc. Merrimack Pharmaceuticals Inc. Vertex Pharmaceuticals Allscripts Healthcare Solutions, 9:30 AM Medicis Pharmaceutical Corp. Lonza Group Ltd Henry Schein Inc. Surgical Care Affiliates Incorporated Inc. 10:00 AM Medtronic, Inc. WellPoint, Inc. Onyx Pharmaceuticals Inc. Sigma-Aldrich Corporation Align Technology Inc.* Symphogen 10:30 AM Room Not Available Medco Health Solutions, Inc. Smith & Nephew plc* Medivation, Inc. Lexicon Pharmaceuticals, Inc. Zeltiq Aesthetics 11:00 AM Room Not Available Merck KGaA Perrigo Company Healthways Incorporated BioMimetic Therapeutics, Inc. Penumbra, Inc. 11:30 AM Room Not Available Dendreon Corporation Gen-Probe Inc. Select Medical Corporation ArthroCare Corporation PTC Therapeutics, Inc. 12:00 PM Luncheon & Keynote: Nancy-Ann DeParle - Counselor to the President and Director of the White House Office of Health Reform, Grand Ballroom Endo Pharmaceuticals Holdings 1:30 PM Room Not Available Amylin Pharmaceuticals Inc.
    [Show full text]
  • Celera CORP Form 10-KT Filed 2009-03-25
    SECURITIES AND EXCHANGE COMMISSION FORM 10-KT Transition report pursuant to Rule 13a-10 or 15d-10 Filing Date: 2009-03-25 | Period of Report: 2008-12-27 SEC Accession No. 0001193125-09-063099 (HTML Version on secdatabase.com) FILER Celera CORP Mailing Address Business Address 1401 HARBOR BAY 1401 HARBOR BAY CIK:1428156| IRS No.: 262028576 | State of Incorp.:DE | Fiscal Year End: 0630 PARKWAY PARKWAY Type: 10-KT | Act: 34 | File No.: 001-34116 | Film No.: 09704683 ALAMEDA CA 94502 ALAMEDA CA 94502 SIC: 8731 Commercial physical & biological research 510-749-4200 Copyright © 2014 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KT ¨ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED x TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM JULY 1, 2008 TO DECEMBER 27, 2008 COMMISSION FILE NUMBER: 001-34116 Celera Corporation (Exact name of registrant as specified in its charter) Delaware 26-2028576 (State or other jurisdiction (I.R.S. Employer of incorporation) Identification No.) 1401 Harbor Bay Parkway Alameda, CA 94502 (Address of principal executive offices, with zip code) (510) 749-4200 (Registrants telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Name of Each Exchange on Which Title of Each Class Registered Common Stock, $.01 par value The NASDAQ Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • In the Court of Chancery of the State of Delaware In
    IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE CELERA CORPORATION Consolidated SHAREHOLDER LITIGATION C.A. No. 6304-VCP VERIFIED CONSOLIDATED AMENDED CLASS ACTION COMPLAINT Plaintiff New Orleans Employees’ Retirement System (“NOERS”) on behalf of itself and all other similarly situated public shareholders of Celera Corporation (hereafter, “Celera” or the “Company”), bring the following Verified Consolidated Amended Class Action Complaint (the “Complaint”) against the members of the board of directors of Celera (the “Celera Board” or the “Board”) for breaching their fiduciary duties, and against Quest Diagnostics Incorporated (“Quest”) and Spark Acquisition Corporation (“Spark”) for aiding and abetting the same. The allegations of the Complaint are based on the knowledge of Plaintiff as to itself, and on information and belief, including the investigation of counsel and review of publicly available information as to all other matters. INTRODUCTION 1. This is a case about a corporate board that chose to negotiate an all-cash sale of the company while operating under the same material conflict of interest that lay at the heart of the Delaware Supreme Court’s ruling in Revlon, Inc. v. MacAndrews & Forbes, Inc., 506 A.2d 173 (Del. 1986). During the past two years, the Celera Board struggled with a multitude of improper accounting practices. These practices caused the Company to issue numerous financial restatements, and resulted in a number of related lawsuits. In the face of mounting personal liability, the Celera Board struck a deal to sell the Company in exchange for broad indemnification and lucrative continued employment. 2. On March 17, 2011, Celera entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Quest, whereby Quest would, within a week of the deal’s announcement, commence a tender offer (the “Tender Offer”) to acquire all of the issued and outstanding shares of Celera common stock for $8.00 per share in cash (the “Proposed Transaction”).
    [Show full text]
  • Human Genome Project
    Human Genome Project The Human Genome Project (HGP) was an international scientific research project with the goal of determining the sequence of nucleotide base pairs that make up human DNA, and of identifying and mapping all of the genes of the human genome from both a physical and a functional standpoint.[1] It remains the world's largest collaborative biological project.[2] After the idea was picked up in 1984 by the US government when the planning started, the project formally launched in 1990 and was declared complete in 2003[3]. Funding came from the US government through the National Institutes of Health (NIH) as well as numerous other groups from around the world. A parallel project was conducted outside government by the Celera Corporation, or Celera Genomics, which was formally launched in 1998. Most of the government-sponsored sequencing was performed in twenty universities and research centers in the United States, the United Kingdom, Japan, France, Logo HGP; Vitruvian Man, Leonardo Germany, Spain and China.[4] da Vinci The Human Genome Project originally aimed to map the nucleotides contained in a human haploid reference genome (more than three billion). The "genome" of any given individual is unique; mapping the "human genome" involved sequencing a small number of individuals and then assembling these together to get a complete sequence for each chromosome. Therefore, the finished human genome is a mosaic, not representing any one individual. Contents Human Genome Project History State of completion Applications and proposed
    [Show full text]
  • Classical Genetics 3. the Beginnings of Genomic Biol
    Table of Contents: Preface 3.3.2. Eukaryotic chromosome structure Websites of Interest 3.3.3. Heterochromatin & Euchromatin 3.4. DNA Replication Glossary 3.4.1. DNA replication is semiconservative 1. Introduction 3.4.2. DNA polymerases 1.1. What is a Gene? 3.4.3. Initiation of replication 1.2. What is a Genome? 3.4.4. DNA replication is semidiscontinuous 1.3. What is Genomic Biology? 3.4.5. DNA replication in Eukaryotes. 1.3.1. Structural Genomics 3.4.6. Replicating ends of chromosomes 1.3.2. Comparative Genomics 3.5. Transcription 1.3.3. Functional Genomics 3.5.1. Cellular RNAs are transcribed from DNA 1.4. Genomic Databases 3.5.2. RNA polymerases catalyze transcription 3.5.3. Transcription in Prokaryotes 2. The beginnings of Genomic Biology – classical 3.5.4. Transcription in Prokaryotes - Polycistronic mRNAs genetics are produced from operons 2.1. Mendel & Darwin – traits are conditioned by genes 3.5.5. Beyond Operons – Modification of expression in 2.2. Genes are carried on chromosomes Prokaryotes 2.3. The chromosomal theory of inheritance 3.5.6. Transcriptions in Eukaryotes 2.4. Additional Complexity of Mendelian Inheritance 3.5.7. Processing primary transcripts into mature mRNA 2.4.1. Multiple alleles 3.6. Translation 2.4.2. Incomplete dominance and co-dominance 3.6.1. The Nature of Proteins 2.4.3. Sex linked inheritance 2.4.4. Epistasis 3.6.2. The Genetic Code 2.4.5. Epigenetics 3.6.3. tRNA – The decoding molecule 2.5. The Law of Independent Assortment 3.6.4.
    [Show full text]
  • Applied Biosystems Inc
    SECURITIES AND EXCHANGE COMMISSION FORM 10-K Annual report pursuant to section 13 and 15(d) Filing Date: 2008-08-27 | Period of Report: 2008-06-30 SEC Accession No. 0001193125-08-185524 (HTML Version on secdatabase.com) FILER APPLIED BIOSYSTEMS INC. Mailing Address Business Address 301 MERRITT 7 301 MERRITT 7 CIK:77551| IRS No.: 061534213 | State of Incorp.:DE | Fiscal Year End: 0630 NORWALK CT 06851 NORWALK CT 06851 Type: 10-K | Act: 34 | File No.: 001-04389 | Film No.: 081042769 2038402000 SIC: 3826 Laboratory analytical instruments Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2008 Or ¨ Transition Report Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-04389 Applied Biosystems Inc. (Exact name of registrant as specified in its charter) DELAWARE 06-1534213 (State or other jurisdiction of (I.R.S. Employer Identification No.) Incorporation or organization) 301 Merritt 7 06851-1070 (Address of principal executive offices) (Zip Code) Registrants telephone number, including area code: 203-840-2000 Securities registered pursuant to Section 12(b) of the Act: Name of Each Exchange Title of Each Class on Which Registered Applied Biosystems Group Common Stock (par value $0.01 per New York Stock Exchange share) Rights to Purchase Series A Participating Junior New York Stock Exchange Preferred Stock (par value $0.01 per share) Celera Group Common Stock (par value $0.01 per share) N/A Rights to Purchase Series B Participating Junior N/A Preferred Stock (par value $0.01 per share) Securities registered pursuant to Section 12(g) of the Act: None Copyright © 2012 www.secdatabase.com.
    [Show full text]
  • Evolution of Cancer Genomics and Its Clinical Implications
    Journal of Pediatrics and Neonatal Care Research Article Open Access Evolution of cancer genomics and its clinical implications Introduction Volume 9 Issue 6 - 2019 Genomics is defined as the study of genes and their functions, and Muhammad Tawfique related techniques while genetics is the study of heredity.1,2 The main Pediatrics and Pediatric Hematology and Oncology, Bangladesh difference between genomics and genetics is that genetics scrutinizes Specialized Hospital, Bangladesh the function and composition of the single gene whereas genomics Correspondence: Muhammad Tawfique, Pediatrics and addresses all genes and their inter-relationships in order to identify Pediatric Hematology and Oncology, Bangladesh Specialized their combined influence on the growth and development of the Hospital, 21 Shyamoly, Mirpur Road, Dhaka 1207, Bangladesh, organism. Thus, genomics is an interdisciplinary field of biology that Email focus on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism’s complete set of DNA, including Received: June 24, 2019 | Published: December 24, 2019 all of its genes. It refers to the study of individual genes and their roles in inheritance. Objectives of genomics are collective characterization and quantification of all of an organism’s genes as well as their interrelationship and influence on the organism.3 Genes may direct the of oncogenomics is to identify new oncogenes or tumor suppressor production of proteins with the assistance of enzymes and messenger genes that may provide new insights into cancer diagnosis, predicting molecules. In turn, proteins make up body structures such as organs clinical outcome of cancers and new targets for cancer therapies. The and tissues as well as control chemical reactions and carry signals success of targeted cancer therapies such as Gleevec, Herceptin and between cells.
    [Show full text]
  • New DNA Sequencing Technologies
    Viikki Science Park 1999 Lars Paulin New DNA sequencing technologies DNA Sequencing and Genomics Institute of Biotechnology University ofof HelsinkiHelsinki http://www.biocenter.helsinki.fi/bi/DNA/ Lars Paulin Institute of Biotechnology University of Helsinki DNADNA SequencingSequencing LaboratoryLaboratory Cultivator 2, Viikinkaari 4 Started in 1990 with DNA Synthesis 1991 DNA Sequencing 1994 EU Yeast Genome Project 1999 - 2000 High-throughput pipeline 1999 – 2002 Five EST Sequencing Projects 2003 First Microbe Genome Project – Move together with Microarray Laboratory to Cultivator 2 2006 Genome Sequencer 20 Core Facility – Service DNA sequencing and whole projects – Collaborative projects ”Research hotel” – Develope high-throughput methods – Consulting Lars Paulin Institute of Biotechnology University of Helsinki DNA Sequencing and Microarray Pipe-Line Bacterial growth Sequencers – QPix Colony Picker – ABI 3130 16-Capillary Sequencer – QFill 2 Microplate filler – ABI 3730 48-Capillary Sequencer – 4 Multidrop 96 and 384 well – Genome Sequencer 20 – 4 Titramax shakers Centrifuges PCR – 2 Eppendorf 5810 – 1 Eppendorf 5804 – 1 Tetrad MjResearch [1 x 96, 3 x (2x48)] – 1 Beckman – 2 Tetrad MjResearch ( 4 x 96 ) Other – 1 Eppendorf Mastercycler (384) – Tecan SpectraFluor Microplate Reader – 1 ABI 9700 ( 2 x 384 ) – ImageMaster VDS, GE Healthcare – 4 ABI 9700 ( 96 ) – 8 Servers for analysis Robotics Phred, Staden Program, – Qiagen Biorobot 9600 AceDB, ARB etc. – Qiagen Biorobot 8000 – SUN cluster – ABI Prism 7000 – Qiagen Biorobot 3000 ( 2m
    [Show full text]
  • (Precision) Medicine
    9/23/2014 Disclosures Personalized (Precision) I am an employed by Promega Corporation, a Madison Medicine based international biotechnology company Promega does not market any of the products mentioned in Wisconsin Association of Physician Assistants this presentation, although we do provide components to some of the manufacturers of these diagnostic assays October 10, 2014 Ashley G. Anderson Jr., MD, MS Chief Medical Officer Promega Corporation Objectives Promega Corporation Look into the future, and appreciate the growing role, and limitless potential, of molecular diagnostics Understand the term “personalized medicine” Be motivated to read, learn, and become an early adopter of precision diagnostics Appreciate that these bill be big changes, but they may not come fast. 1 9/23/2014 Personalized medicine Precision medicine “The molecular methods that make personalized medicine The tests themselves are not necessarily “personalized.” possible include testing for variations in genes, gene expression, They are standardized like most other tests proteins and metabolites as well as new treatments that target molecular mechanisms. Test results are correlated with clinical The results from these tests are increasingly more predictive factorsfactors--suchsuch as disease state, prediction of futurfuturee disease states, of disease states drug response, and treatment prognosisprognosis--toto help physiciansphysicians Certain tests are more predictive of responses to specific individualize treatment for each patient” therapies Personalized Medicine
    [Show full text]
  • Human Genome Project the Human
    Human Genome Project From Wikipedia, the free encyclopedia The Human Genome Project (HGP) was an international scientific research project with a primary goal to determine the sequence of chemical base pairs which make up DNA and to identify and map the approximately 20,000–25,000 genes of the human genome from both a physical and functional standpoint. The first available assembly of the genome was completed in 2000 by the UCSC Genome Bioinformatics Group, composed of Jim Kent (then a UCSC graduate student of molecular, cell and developmental biology), Patrick Gavin, Terrence Furey and David Kulp. The project began in 1990, initially headed by James D. Watson at the U.S. National Institutes of Health. A working draft of the genome was released in 2000 and a complete one in 2003, with further analysis still being published. A parallel project was conducted outside of government by the Celera Corporation. Most of the government-sponsored sequencing was performed in universities and research centers from the United States, the United Kingdom, Canada, and New Zealand. The mapping of human genes is an important step in the development of medicines and other aspects of health care. The HGP originally aimed to map the nucleotides contained in a haploid reference human genome (more than three billion). Several groups have announced efforts to extend this to diploid human genomes including the International HapMap Project, Applied Biosystems, Perlegen, Illumina, JCVI, Personal Genome Project, and Roche-454. The "genome" of any given individual (except for identical twins and cloned organisms) is unique; mapping "the human genome" involves sequencing multiple variations of each gene.
    [Show full text]
  • Computational Methods for Analysis of Single Molecule Sequencing Data
    Computational Methods for Analysis of Single Molecule Sequencing Data by Ehsan Haghshenas M.Sc., University of Western Ontario, 2014 B.Sc., Isfahan University of Technology, 2012 Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the School of Computing Science Faculty of Applied Sciences c Ehsan Haghshenas 2020 SIMON FRASER UNIVERSITY Spring 2020 Copyright in this work rests with the author. Please ensure that any reproduction or re-use is done in accordance with the relevant national copyright legislation. Approval Name: Ehsan Haghshenas Degree: Doctor of Philosophy (Computing Science) Title: Computational Methods for Analysis of Single Molecule Sequencing Data Examining Committee: Chair: Diana Cukierman University Lecturer Binay Bhattacharya Senior Supervisor Professor S. Cenk Sahinalp Co-Supervisor Senior Investigator Center for Cancer Research National Cancer Institute Cedric Chauve Co-Supervisor Professor Faraz Hach Co-Supervisor Assistant Professor Department of Urologic Sciences The University of British Columbia Senior Research Scientist Vancouver Prostate Centre Martin Ester Internal Examiner Professor Mihai Pop External Examiner Professor Department of Computer Science University of Maryland, College Park Date Defended: March 26, 2020 ii Abstract Next-generation sequencing (NGS) technologies paved the way to a significant increase in the number of sequenced genomes, both prokaryotic and eukaryotic. This increase provided an opportunity for considerable advancement in genomics and precision medicine. Although NGS technologies have proven their power in many applications such as de novo genome assembly and variation discovery, computational analysis of the data they generate is still far from being perfect. The main limitation of NGS technologies is their short read length relative to the lengths of (common) genomic repeats.
    [Show full text]